Cargando…

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease

Treatment beyond progressive disease (PD) is a concept that even after drugs become ineffective, their continued use is more beneficial for patients than their discontinuation. In recent years, a concept of bevacizumab beyond PD (BBP) has attracted attention in the treatment of various cancers, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoji, Tadahiro, Eto, Hisashi, Sato, Takanori, Soma, Rikako, Fukagawa, Daisuke, Tomabechi, Hidetoshi, Takatori, Eriko, Nagasawa, Takayuki, Sato, Seiya, Kagabu, Masahiro, Baba, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787582/ https://www.ncbi.nlm.nih.gov/pubmed/31546963 http://dx.doi.org/10.3390/healthcare7030109

Ejemplares similares

Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
por: Takeuchi, Satoshi, et al.
Publicado: (2020)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX
por: Takatori, Eriko, et al.
Publicado: (2013)

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
por: Takatori, Eriko, et al.
Publicado: (2014)

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer
por: Watanabe, Takafumi, et al.
Publicado: (2020)

Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
por: Kagabu, Masahiro, et al.
Publicado: (2023)

Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma
por: Sato, Chie, et al.
Publicado: (2020)

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2017)

Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens
por: Shoji, Tadahiro, et al.
Publicado: (2014)

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
por: Nonaka, Michiko, et al.
Publicado: (2018)

ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab
por: Inoue, Akihiro, et al.
Publicado: (2021)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy
por: Shoji, Tadahiro, et al.
Publicado: (2020)

Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers
por: Fukagawa, Daisuke, et al.
Publicado: (2018)

Mast cells partially contribute to mucosal adjuvanticity of surfactin in mice
por: Yoshino, Naoto, et al.
Publicado: (2017)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Cartilage repair and inhibition of the progression of cartilage degeneration after transplantation of allogeneic chondrocyte sheets in a nontraumatic early arthritis model
por: Takatori, Naoki, et al.
Publicado: (2018)

Case of Repeated Full-Thickness Macular Hole Formations and Spontaneous Closure following Intravitreal Bevacizumab Treatment for Central Retinal Vein Occlusion
por: Furukawa, Rika, et al.
Publicado: (2022)

MON-013 Effect of Poor Circumstance in Utero on Adiponectin Gene Expressions Through Epigenetic Changes in Offspring
por: Masuyama, Hisashi, et al.
Publicado: (2020)

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2014)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
por: Kubota-Taniai, Mariko, et al.
Publicado: (2011)

Development of CRTEIL and CETRIZ, Cre-loxP-Based Systems, Which Allow Change of Expression of Red to Green or Green to Red Fluorescence upon Transfection with a Cre-Expression Vector
por: Ohtsuka, Masato, et al.
Publicado: (2009)

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report
por: Kataoka, Nobutaka, et al.
Publicado: (2021)

Ocular syphilis with optic disc neovascularization treated with bevacizumab evaluated by OCT angiography and electroretinography
por: Miura, Gen, et al.
Publicado: (2020)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
por: FUJII, Masazumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ma4t72uahgg1k43vbpj8pi9pla